ATOS
Price
$0.89
Change
+$0.01 (+1.14%)
Updated
Jun 27 closing price
Capitalization
115.19M
50 days until earnings call
MGNX
Price
$1.19
Change
-$0.08 (-6.30%)
Updated
Jun 27 closing price
Capitalization
75.08M
44 days until earnings call
Interact to see
Advertisement

ATOS vs MGNX

Header iconATOS vs MGNX Comparison
Open Charts ATOS vs MGNXBanner chart's image
Atossa Therapeutics
Price$0.89
Change+$0.01 (+1.14%)
Volume$16.36M
Capitalization115.19M
MacroGenics
Price$1.19
Change-$0.08 (-6.30%)
Volume$9.54M
Capitalization75.08M
ATOS vs MGNX Comparison Chart in %
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. MGNX commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and MGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ATOS: $0.89 vs. MGNX: $1.19)
Brand notoriety: ATOS and MGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 1519% vs. MGNX: 698%
Market capitalization -- ATOS: $115.19M vs. MGNX: $75.08M
ATOS [@Biotechnology] is valued at $115.19M. MGNX’s [@Biotechnology] market capitalization is $75.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileMGNX’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • MGNX’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than MGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 6 TA indicator(s) are bullish while MGNX’s TA Score has 2 bullish TA indicator(s).

  • ATOS’s TA Score: 6 bullish, 1 bearish.
  • MGNX’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than MGNX.

Price Growth

ATOS (@Biotechnology) experienced а +12.89% price change this week, while MGNX (@Biotechnology) price change was -13.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

MGNX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($115M) has a higher market cap than MGNX($75.1M). ATOS YTD gains are higher at: -5.540 vs. MGNX (-63.385). ATOS has higher annual earnings (EBITDA): -28.04M vs. MGNX (-47.33M). MGNX has more cash in the bank: 154M vs. ATOS (65.1M). ATOS has less debt than MGNX: ATOS (0) vs MGNX (37.5M). MGNX has higher revenues than ATOS: MGNX (152M) vs ATOS (0).
ATOSMGNXATOS / MGNX
Capitalization115M75.1M153%
EBITDA-28.04M-47.33M59%
Gain YTD-5.540-63.3859%
P/E RatioN/AN/A-
Revenue0152M-
Total Cash65.1M154M42%
Total Debt037.5M-
FUNDAMENTALS RATINGS
ATOS vs MGNX: Fundamental Ratings
ATOS
MGNX
OUTLOOK RATING
1..100
4386
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5091
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is somewhat better than the same rating for MGNX (80) in the Biotechnology industry. This means that ATOS’s stock grew somewhat faster than MGNX’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MGNX (100) in the Biotechnology industry. This means that ATOS’s stock grew similarly to MGNX’s over the last 12 months.

ATOS's SMR Rating (97) in the Medical Specialties industry is in the same range as MGNX (97) in the Biotechnology industry. This means that ATOS’s stock grew similarly to MGNX’s over the last 12 months.

ATOS's Price Growth Rating (50) in the Medical Specialties industry is somewhat better than the same rating for MGNX (91) in the Biotechnology industry. This means that ATOS’s stock grew somewhat faster than MGNX’s over the last 12 months.

MGNX's P/E Growth Rating (95) in the Biotechnology industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that MGNX’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSMGNX
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PTBRY12.800.49
+3.98%
PT Bank Negara Indonesia TBK
ANZFF0.35N/A
N/A
Air New Zealand Ltd.
BLYQ0.13N/A
N/A
Bally Corp.
MTGRY2.20N/A
N/A
Mount Gibson Iron Ltd.
FNMAP18.50-0.49
-2.55%
Fannie Mae

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
+1.64%
ABOS - ATOS
46%
Loosely correlated
-7.44%
GBIO - ATOS
44%
Loosely correlated
-15.40%
IMNM - ATOS
43%
Loosely correlated
-0.23%
MGNX - ATOS
43%
Loosely correlated
-6.30%
NRIX - ATOS
43%
Loosely correlated
+0.17%
More

MGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with CRBU. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGNX
1D Price
Change %
MGNX100%
-6.30%
CRBU - MGNX
51%
Loosely correlated
-5.19%
XNCR - MGNX
51%
Loosely correlated
-3.10%
RGNX - MGNX
47%
Loosely correlated
-4.11%
SYRE - MGNX
46%
Loosely correlated
-4.99%
BEAM - MGNX
46%
Loosely correlated
-1.98%
More